Avillion announces US approval of Pfizer’s BOSULIF®

Avillion Announces US Approval of Pfizer’s BOSULIF® (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML).

Approval is based on the successful BFORE Phase 3 study conducted by Avillion under a collaborative development agreement with Pfizer.

Please read the full press release here.

TwitterLinkedInEmailPrint